Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $43.
August 19, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners, maintaining a price target of $43, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $43 by a reputable analyst suggests positive sentiment and potential upside for Surgery Partners. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100